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CARDIOVASCULAR RISK FACTORS AMONG HISPANIC AND NON-
HISPANIC WHITE ADULTS IN THE UNITED STATES
McDonald M1, Lustik MB2
1Pﬁzer Inc, New York, NY, USA, 2Science Applications International Corporation, Reston, 
VA, USA
OBJECTIVES: Current prevalence of cardiovascular risk factors are lacking among 
Hispanic adults. This study contributes to our knowledge by examining current 
national estimates for hypertension, high cholesterol, diabetes and obesity among 
Hispanic and non-Hispanic white adults aged 20 years and older, by gender and age 
group. METHODS: Cross-sectional observational study design. Analysis of adults 20 
years and older surveyed in the Behavioral Risk Factor Surveillance System (BRFSS) 
2007 (Hispanic = 26,254, Non-Hispanic white = 332,828) and 2008 (Hispanic = 
23,325, Non-Hispanic white = 320,417). RESULTS: Among Hispanic adults (28.8 
million), the age-adjusted prevalence of hypertension is 26%, similar to the 27% 
prevalence among the 149.5 million white adults. Diabetes is signiﬁcantly more preva-
lent among Hispanics (13% vs. 7%). Hispanic women have nearly twice the rate of 
diabetes as white women, (13% vs.7%), and Hispanics aged 65 years and older have 
a signiﬁcantly higher prevalence of diabetes than older, white adults (30% vs. 17%). 
High cholesterol is equally prevalent in Hispanic and white adults, 36% and 35%, 
respectively. Obesity rates for Hispanic adults aged 20–39, 40–64, and 65+ are 27%, 
36%, and 28%, respectively. Obesity rates for non-Hispanic white adults aged 20–39, 
40–64, and 65+ are 24%, 29%, and 22%, respectively (p < 0.001 for all obesity 
differences). CONCLUSIONS: Age-adjusted prevalence rates of hypertension and high 
cholesterol are similar among Hispanic and non-Hispanic white adults. The prevalence 
of diabetes and obesity is signiﬁcantly higher in the Hispanic population, dispropor-
tionately affecting women and older adults. Effective approaches are needed to reduce 
these health disparities.
PCV37
VENOUS THROMBOEMBOLISM IN THE SINGAPOREAN POPULATION—
THE NEED TO REVISIT RISK ASSESSMENT TOOLS FOR PROPHYLAXIS
Molina JAD, Heng BH
National Healthcare Group, Singapore, Singapore, Singapore
OBJECTIVES: The identiﬁcation of risk factors for venous thromboembolism (VTE) 
has led to the establishment of standards of prevention and care in many Western 
countries. Despite the growing evidence of lower VTE risk among Asians, risk assess-
ment tools used in North America and Europe do not take this into consideration. 
This study describes the incidence of VTE among Asians, Caucasians and Eurasians 
in Singapore. METHODS: This is a cross-sectional study using data from the Opera-
tions Data Store (ODS) administrative database of the National Healthcare Group 
(NHG) cluster of health facilities in Singapore. Total admissions, cases of VTE and 
demographic characteristics of patients admitted to the 3 acute care hospitals of NHG 
in 2006 were obtained from the ODS. A diagnosis of VTE was based on the ICD-9CM 
code assigned to the patient. Age and gender-speciﬁc rates, as well as incidence of 
overall and secondary VTE (cases which developed during admission) among Asians, 
Caucasians and Eurasians was estimated. RESULTS: Out of 98,121 patients, 860 had 
VTE. The age-adjusted rate for total and secondary VTE was 73 and 54 per 10,000 
admissions, respectively. Incidence of VTE increased with age, and was higher in 
females. Total VTE rates for Caucasians and Eurasians were 241 and 122 per 10,000 
admissions, respectively. Rates for Chinese, Malays and Indians were 93, 100 and 62 
per 10,000 admissions, respectively. Secondary VTE rates for Caucasians and Eur-
asians were 201 and 122 per 10,000 admissions, respectively, while rates for Chinese, 
Malays and Indians were 71, 74 and 43 per 10,000, respectively. CONCLUSIONS: 
The incidence of secondary VTE may be at least 40% lower for Asians compared to 
Caucasians and Eurasians. Improvements in VTE risk assessment will lead to more 
targeted prophylaxis, thus resulting in more acceptable and cost-effective care.
PCV38
RELATIONSHIP BETWEEN ADMITTING (NON-FASTING) BLOOD 
GLUCOSE AND IN-HOSPITAL MORTALITY STRATIFIED BY DIABETES 
MELLITUS AMONG ACUTE CORONARY SYNDROME PATIENTS IN 
OMAN
Panduranga P1, Sulaiman K1, Al-Zakwani IS2
1Royal Hospital, Muscat, Oman, 2Sultan Qaboos University, Muscat, Oman
OBJECTIVES: To evaluate the relationship between admitting (non-fasting) blood 
glucose and in-hospital mortality in patients with and without diabetes mellitus pre-
senting with acute coronary syndrome (ACS) in Oman. METHODS: Data were 
analyzed from 1551 consecutive patients admitted to 15 hospitals throughout Oman 
with the ﬁnal diagnosis of ACS during January to June 2007, as part of Gulf RACE 
(Registry of Acute Coronary Events). Admitting blood glucose was divided into four 
groups; namely, euglycemia (≤7 mmol/l), mild hyperglycemia (>7 to <9 mmol/l), mod-
erate hyperglycemia (≥9 to <11 mmol/l), and severe hyperglycemia (≥11 mmol/l). 
Analyses were performed using descriptive and multivariate statistical techniques. 
RESULTS: Thirty-eight percent (n = 584) and 62% (n = 967) of the patients were 
documented with and without a history of diabetes mellitus, respectively. In non-
diabetic ACS patients, there was a near-linear relationship between admitting blood 
glucose and in-hospital mortality. Non-diabetic patients with severe hyperglycemia 
were associated with signiﬁcantly higher in-hospital mortality compared to those with 
euglycemia (13.1% versus 1.52%; p < 0.001), mild hyperglycemia (13.1% versus 
3.62%; p = 0.003) and even moderate hyperglycemia (13.1% versus 4.17%; p = 
0.034). Even after multivariate adjustment, severe hyperglycemia was still associated 
with higher in-hospital mortality when compared to both euglycemia (odds ratio (OR), 
6.3; p < 0.001) and mild hyperglycemia (OR, 3.42; p = 0.011). No signiﬁcant relation-
ship was noted between admitting blood glucose and in-hospital mortality among 
diabetic ACS patients even after multivariable adjustment (all p-values >0.05). CON-
CLUSIONS: Admission hyperglycemia is common in ACS patients and is associated 
with higher in-hospital mortality among those patients with previously unreported 
diabetes mellitus.
PCV39
THE PUERTO RICO CARDIOVASCULAR RISK ESTIMATION STUDY 
(PRCARES): AN EXPLORATORY ASSESSMENT OF NEW PATIENTS IN 
PHYSICIANS’ OFFICES
Monsanto HA1, Renta A2, Dones W3, Cidre C4, Comulada AL5, Orengo JC1
1MSD Caribbean, Carolina, PR, USA, 2Conaway, Renta y Asociados, San Juan, PR, USA, 
3Private Practice, Humacao, PR, USA, 4Private Practice, Manati, PR, USA, 5Instituto de 
Endocrinología, Diabetes y Metabolismo, Toa Baja, PR, USA
OBJECTIVES: To understand the risk of developing cardiovascular disease in a 
sample of Puerto Ricans through analysis of the10-yr risk Framingham Risk Score for 
developing coronary heart disease (CHD) of patients undergoing ﬁrst visit at private 
practices in Puerto Rico. METHODS: Exploratory cross-sectional record review study 
of 500 consecutive patients whose ﬁrst visit occurred on or after July 1, 2007 to the 
ofﬁces of four physicians. Records of new patients 35 years or older with recent labo-
ratory values that included a lipid proﬁle and a fasting glucose level were selected. 
Data collected included patient information, clinical parameters, and medication 
therapy at ﬁrst visit. RESULTS: Preliminary analysis of 336 patients is presented. Most 
patients were female (59%) and the average age was 59. Eighty percent of those with 
documented height and weight were either overweight (40.4%) or obese (39.6%). Less 
than a third (27%) was on dietary restriction and 12% were physically active based 
on patient history. Seven of 10 had hypertension, 37.8% had dyslipidemia and 37.5% 
had diabetes. Nearly one-third had two comorbidities. More than 60% percent were 
at goal for lipid, blood pressure and blood glucose parameters, with the exception of 
LDL cholesterol and systolic blood pressure where 42% were at goal. Men were nearly 
ﬁve times more likely to have a 10% or greater 10-yr CHD risk than females (59.7% 
vs. 13.2%, respectively) using the Framingham Risk Score. CONCLUSIONS: In this 
exploratory study, patients undergoing ﬁrst visit at private practices in Puerto Rico 
were found to have multiple risk factors that may lead to CHD, including obesity, 
lack of exercise, hypertension, high LDL levels and high systolic blood pressure. This 
information may be used as a basis for larger CHD risk estimation studies which could 
be important to establish primary prevention strategies for the general population.
PCV40
HEALTH DISPARITIES IN MODIFIABLE RISK FACTORS FOR CORONARY 
HEART DISEASE: A COMPARISON OF APPALACHIAN TO NON-
APPALACHIAN PORTIONS OF APPALACHIAN STATES
Blake KB1, Halverson J2
1West Virginia University School of Pharmacy, Morgantown, WV, USA, 2West Virginia 
University, Morgantown, WV, USA
OBJECTIVES: To determine if there are geographic disparities in behavioral risk 
factors for coronary heart disease in Appalachian versus non-Appalachian portions of 
Appalachian states. METHODS: Using Behavioral Risk Factor Surveillance System 
(BRFSS) data from 2000 to 2005, county codes were utilized to identify resident 
locations for 1,567,206 respondents residing in states that are located partly (twelve 
states) or entirely (one state) within the Appalachian region, as designated by the 
Appalachian Regional Commission. Prevalence of modiﬁable risk factors of cardio-
vascular disease (obesity, physical inactivity, low intake of fruit and vegetables, and 
smoking) in the Appalachian portions of states was compared to that in the non-
Appalachian portions. Chi square tests were utilized to test for signiﬁcant differences. 
RESULTS: Overall, obesity rates were higher in the Appalachian region compared to 
the non-Appalachian region. When compared within each individual state, obesity 
rates were signiﬁcantly higher in the Appalachian portion compared to the non-
Appalachian portion in seven states. Overall, fewer respondents participated in leisure 
time physical activity in the Appalachian region, and this trend held in eight states. 
Respondents in the Appalachian region were less likely to eat ﬁve or more servings of 
fruits/vegetables per day, and this trend held in nine states. Finally, more subjects 
reported smoking every day in the Appalachian region, which held true in ten states. 
Gender differences in the Appalachian region mirrored the trends in non-Appalachian 
areas. Prevalence of physical inactivity was higher in women, as was daily consump-
tion of the recommended amount of fruits and vegetables. Smoking rates were gener-
ally higher in men. CONCLUSIONS: In general, the Appalachian region was 
associated with higher prevalence of modiﬁable risk factors for coronary heart disease, 
possibly explaining the increased burden of heart disease in this population. These 
data highlight a culture of poor diet and sedentary lifestyle prevalent in Appalachian 
populations.
PCV41
A DECADE OF STATIN LABORATORY TEST MONITORING IN THE 
UNITED STATES (1997–2007): A COHORT STUDY
Slejko JF, Anderson HD, Valuck RJ
University of Colorado Denver, Aurora, CO, USA
OBJECTIVES: The objective of this study was to explore rates of baseline and follow-
up liver enzyme and baseline creatine kinase (CK) testing in new statin users. 
METHODS: The PharMetrics Integrated Outcomes Database was used to obtain 
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medical claims records for continuously enrolled adult (≥18 years) ﬁrst-time statin 
users. Patients were followed for one year. Liver enzyme and CK tests were identiﬁed 
using CPT-4 procedure codes. Descriptive statistics were used to characterize the 
population and estimate unadjusted associations between laboratory monitoring and 
patient characteristics. Multivariable logistic regression was used to estimate the odds 
of monitoring, controlling for age, gender, number of prescription drugs during statin 
use, diabetes, statin intensity, prescribing physician specialty, geographic region and 
health plan type. RESULTS: Between July 1, 1997 and March 31, 2007, there were 
66,228 new statin users in the study population. 14% of new users were given a liver 
enzyme test at baseline and 25% received follow-up tests. 3% of new users were given 
baseline CK tests. Odds of compliant baseline and follow-up liver enzyme testing were 
higher for those with previous liver disease (OR = 3.0, P < 0.0001) and diabetes (OR 
= 1.2, P < 0.0001). Cardiologists were less likely to order liver tests than family or 
general practitioners (OR = 0.68, P < 0.0001). It was estimated that about 19,000 
patients were indicated for a baseline CK test, based on risk factors, but only 2.6% 
of those patients received one. The odds of receiving compliant baseline CK tests 
increased for patients receiving high potency statins (OR = 1.7, P < 0.01). Cardiologists 
were more likely to order CK tests than family or general practitioners (OR = 1.8, P 
< 0.001). CONCLUSIONS: While rates of laboratory testing were low, adjusted odds 
suggest that patients at higher risk for adverse outcomes are more likely to receive 
compliant liver enzyme and CK monitoring.
PCV42
INPATIENT MORTALITY AND HOSPITALIZATION COSTS IN ATRIAL 
FIBRILLATION PATIENTS
Emons MF1, Lin J2, Yu HT1
1Cerner LifeSciences, Beverly Hills, CA, USA, 2Sanoﬁ-Aventis, Bridgewater, NJ, USA
OBJECTIVES: Although atrial ﬁbrillation/ﬂutter (AF) is a risk factor for cardiovas-
cular (CV) disease, its morbidity/mortality burden is uncertain. This retrospective 
cohort study examined CV hospitalization/mortality rates and associated costs among 
AF patients in the real-world setting. METHODS: The US MarketScan® database 
was used to identify adults with AF (≥1 AF hospital discharge or ≥2 non-diagnostic 
outpatient AF claims) and ≥18 months’ continuous enrollment data [≥12 months and 
≥6 months’ immediately before and after the ﬁrst qualifying (index) AF diagnosis] 
between January 2003 and September 2007. AF was classiﬁed as newly-diagnosed 
(ND) or pre-existing (PRE) based on AF diagnoses in the ﬁrst 12 months. CV hospi-
talization and mortality were assessed post-index diagnosis during a mean follow-up 
period of 20 months.RESULTS: Of 184,155 AF patients identiﬁed (mean 73 years, 
55% men), 119,486 had PRE and 64,669 had ND disease; common comorbidities 
included hypertension (60%), heart failure (31%), and diabetes (23%). During post-
index follow-up, 80,523 PRE patients (67%) vs. 51,240 ND patients (79%) were 
hospitalized. Admissions for CV causes were similarly frequent in patients with PRE 
and ND disease (mean 0.30 vs. 0.33 events/patient, respectively) and incurred similar 
costs per event for the two groups (mean US$11,898 vs. $12,257, respectively). Causes 
of CV admission (by DRG) in the overall cohort included cardiac arrhythmia (23%), 
myocardial infarction (3.8%), syncope (3.2%) and ‘other/unspeciﬁed’ (66%). Admis-
sions with an AF diagnosis were more frequent among patients with ND than PRE 
disease (mean 0.99 vs 0.61 events/patient), but hospital costs for the two groups were 
similar (mean US$12,059 vs. $11,984, respectively). In total, 2990 (2.5%) PRE 
patients and 1409 (2.2%) ND patients died in hospital, with most deaths occurring 
during admission with an AF diagnosis (58% in both groups). CONCLUSIONS: AF 
is accompanied by a high level of CV hospitalization with associated cost burden and 
mortality.
CARDIOVASCULAR DISORDERS – Cost Studies
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CLINICAL AND ECONOMIC IMPACT OF BIVALIRUDIN ON BLEEDING 
EVENTS IN HIGH RISK UNSTABLE ANGINA (UA)/NON-ST-ELEVATION 
MYOCARDIAL INFARCTION (NSTEMI) PATIENTS UNDERGOING 
PERCUTANEOUS CORONARY INTERVENTION (PCI) IN FRANCE
Olchanski N1, Slawsky K1, Cyr P1, Schwenkglenks M2, Steinhubl S3
1Boston Healthcare Associates, Boston, MA, USA, 2European Centre of Pharmaceutical 
Medicine (ECPM), Basel, Switzerland, 3The Medicines Company, Zürich-Flughafen, 
Switzerland
OBJECTIVES: Approximately 140,000 percutaneous coronary interventions (PCIs) 
will be performed in France in 2009/2010. PCI complications often increase resource 
utilization. New antithrombotic therapies have the potential to improve outcomes and 
decrease costs. The ACUITY trial demonstrated a decreased mortality and a statisti-
cally signiﬁcant reduction in bleeding events with bivalirudin as compared to a 
heparin-plus-GPI (HEP+GPI) regimen. This analysis evaluated the economic impact 
of this improvement in the French hospital setting with a focus on reduced access 
site- and non-access site-related bleeding events. METHODS: A budget-impact model 
was developed to evaluate the impact of bivalirudin in high-risk (per ESC deﬁnition) 
UA/NSTEMI patients undergoing PCI in a French hospital. Clinical data for the model 
were derived from the ACUITY trial and included 30-day event rates for major com-
plications (total and non-access site bleeding, Q-wave myocardial infarction, repeat 
PCI and coronary artery bypass graft). Economic data were derived from French 
medical literature, including clinical event costs, ward costs (both regular and ICU/
CCU) and pharmaceutical costs. RESULTS: In 100 PCI patients, bivalirudin use would 
result in 4 fewer protocol-deﬁned major bleeding events (3.8%) and 12 fewer minor 
bleeding events (12.2%). Considering non-access site bleeding events only (all bleeds 
excluding retroperitoneal and access site bleeds), bivalirudin use would reduce major 
and minor bleeding events by 0.7% and 4.7%, respectively. Including all bleeding 
events, the total hospital budget impact of treating 100 high risk UA/NSTEMI patients 
using a HEP+GPI-based strategy is 3626,903. Introducing a bivalirudin-based strategy 
could save 332,520 (5%). The reduction in non-access site bleeding events alone could 
result in savings of 318,028 (3%) per 100 patients. CONCLUSIONS: A bivalirudin-
based strategy for anticoagulant use in high risk UA/NSTEMI patients undergoing PCI 
is associated with favorable clinical and economic outcomes when compared with 
HEP+GPI in a French hospital setting.
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BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING 
PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN 
ITALIAN HOSPITALS
Olchanski N1, Slawsky K1, Cyr P1, Schwenkglenks M2
1Boston Healthcare Associates, Boston, MA, USA, 2European Centre of Pharmaceutical 
Medicine (ECPM), Basel, Switzerland
OBJECTIVES: New antithrombotic therapies have the potential to improve clinical 
outcomes and decrease costs. The HORIZONS-AMI study of bivalirudin demon-
strated signiﬁcantly reduced clinical event rates (mortality and bleeding) compared to 
a heparin and glycoprotein IIa/IIIb inhibitor (HEP + GPI) regimen. Approximately 
24,000 PPCIs were performed in Italy in 2008, based on statistics published by GISE. 
The potential clinical and economic value of implementing a bivalirudin-based strategy 
for STEMI patients receiving PPCI is compared to current HEP + GPI-based practice, 
from a typical Italian hospital perspective. METHODS: A budget impact model was 
developed to compare treatment of STEMI patients undergoing PPCI with either 
bivalirudin or HEP + GPI. Clinical data for the model was derived from the HORI-
ZONS-AMI trial, and included 30-day event rates for major complications (protocol 
bleeding, Q-wave myocardial infarction, repeat PCI and coronary artery bypass graft 
procedures). Italian cost and clinical practice data were derived from published 
sources. RESULTS: Overall average procedure costs per HEP + GPI-treated patient 
were 37121. Treating patients with bivalirudin (incorporating 7.2% provisional GPI 
use per HORIZONS-AMI) saved 3529 per patient. In extrapolating these beneﬁts to 
a typical Italian hospital conducting 200 PPCI procedures per year: 2 deaths (1%); 8 
major bleeding events (3.7%); and 14 minor bleeding events (6.8%) could be averted 
if treated with bivalirudin. In addition, introducing a bivalirudin-based strategy to 
treat a typical cohort of 200 STEMI patients would save the hospital budget 3105,807 
(7%) per year. Extrapolating these savings to the total number of PPCI procedures 
performed in Italy in 2008 would result in savings of 31,270,000 in hospital expen-
ditures nationally. CONCLUSIONS: Using a bivalirudin-based strategy in STEMI 
patients undergoing PPCI is associated with favorable clinical and economic outcomes 
when compared with HEP + GPI in an Italian hospital setting.
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BUDGET IMPACT OF BIVALIRUDIN IN STEMI PATIENTS UNDERGOING 
PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PPCI) IN 
GERMAN HOSPITALS
Olchanski N1, Slawsky K1, Cyr P1, Schwenkglenks M2, Zeymer U3
1Boston Healthcare Associates, Boston, MA, USA, 2European Centre of Pharmaceutical 
Medicine (ECPM), Basel, Switzerland, 3Klinikum Ludwigshafen, Ludwigshafen, Germany
OBJECTIVES: Primary percutaneous coronary intervention (PPCI) has become the 
preferred treatment option for acute ST-segment elevation myocardial infarction 
(STEMI). In 2006, nearly 38,000 PPCI procedures were performed in Germany. New 
antithrombotic therapies have the potential to improve clinical outcomes and decrease 
costs. The HORIZONS-AMI study of bivalirudin demonstrated reduced clinical event 
rates (mortality and bleeding) compared to a heparin and GPI (HEP + GPI) regimen. 
The potential economic value of implementing bivalirudin in the PPCI setting is evalu-
ated in this analysis from a German hospital perspective. METHODS: A budget 
impact model was developed to compare treatment of STEMI patients undergoing 
PPCI with either bivalirudin or HEP + GPI. Clinical data for the model were derived 
from the HORIZONS trial database, and included 30-day event rates for major 
complications (bleeding as deﬁned by trial protocol, Q-wave myocardial infarction, 
and repeat PCI and coronary artery bypass graft procedures) and patient death. 
German cost and clinical practice data were derived from published sources, the 
German subset of the HORIZONS trial (n = 786) and the ADONIS registry. 
RESULTS: Overall average procedure cost per bivalirudin-treated patient (incorporat-
ing 7.2% provisional GPI use as per HORIZONS) was 38165, compared with 38,84 
per HEP + GPI-treated patient. In extrapolating these beneﬁts to a typical German 
hospital of 200 PPCI patients per year, 2 deaths (1%), 8 major bleeding events (3.7%), 
and 14 minor bleeding events (6.8%) in patients would be averted if treated with 
bivalirudin. The total hospital budget impact of treating 200 PPCI patients using a 
HEP + GPI based strategy is 31,770,814. Introducing a bivalirudin-based strategy 
could save 3137,817 (8%) per year. CONCLUSIONS: Using a bivalirudin-based 
strategy in STEMI patients undergoing PPCI is associated with favorable clinical and 
economic outcomes when compared with HEP + GPI in a German hospital setting.
